Evidence map›Paper›PMID 30518414›Full record

ArticleBMC research notes2018

Validation of extracellular ligand-receptor interactions by Flow-TriCEPS.

Laura A Lopez-Garcia, Levent Demiray, Sandra Ruch-Marder, Ann-Katrin Hopp, Michael O Hottiger, Paul M Helbling, Maria P Pavlou

Abstract readValidation Study
In one paragraph

Article in BMC research notes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura A Lopez-GarciaDualsystems Biotech A.G., Grabenstrasse 11a, 8952, Schlieren, Switzerland.
Levent DemirayDualsystems Biotech A.G., Grabenstrasse 11a, 8952, Schlieren, Switzerland.
Sandra Ruch-MarderDualsystems Biotech A.G., Grabenstrasse 11a, 8952, Schlieren, Switzerland.
Ann-Katrin HoppDepartment of Molecular Mechanisms of Disease, University of Zurich, 8057, Zurich, Switzerland.
Michael O HottigerDepartment of Molecular Mechanisms of Disease, University of Zurich, 8057, Zurich, Switzerland.
Paul M HelblingDualsystems Biotech A.G., Grabenstrasse 11a, 8952, Schlieren, Switzerland.
Maria P PavlouDualsystems Biotech A.G., Grabenstrasse 11a, 8952, Schlieren, Switzerland. maria.pavlou@dualsystems.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe advent of ligand-based receptor capture methodologies, allows the identification of unknown receptor candidates for orphan extracellular ligands. However, further target validation can be tedious, laborious and time-consuming. Here, we present a methodology that provides a fast and cost-efficient alternative for candidate target verification on living cells.

resultsIn the described methodology a ligand of interest (e.g. transferrin, epidermal growth factor or insulin) was conjugated to a linker (TriCEPS) that carries a biotin. To confirm ligand/receptor interactions, the ligand-TriCEPS conjugates were first added onto living cells and cells were subsequently labeled with a streptavidin-fluorophore and analyzed by flow cytometry (thus referred as Flow-TriCEPS). Flow-TriCEPS was also used to validate identified receptor candidates when combined with a siRNA knock down approach (i.e. reduction of expression levels). This approach is versatile as it can be applied for different classes of ligands (proteins, peptides, antibodies) and different cell lines. Moreover, the method is time-efficient since it takes advantage of the large variety of commercially available (and certified) siRNAs.

Indexed as

BiotinCell Line, TumorErbB ReceptorsFlow CytometryHEK293 CellsHumansHydrazinesInsulinLigandsReproducibility of ResultsRNA, Small InterferingSuccinimidesBiotinErbB ReceptorsHydrazinesInsulinLigandsRNA, Small InterferingSuccinimidesTRICEPS compoundCandidate verificationFlow-TriCEPSHATRICKnock downLRCsiRNA

Identifiers

PMID30518414
PMCPMC6280402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.